Somatostatin Receptor Imaging PET in Neuroendocrine Neoplasm

Forskning

Somatostatin Receptor Imaging PET in Neuroendocrine Neoplasm

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Somatostatin Receptor Imaging PET in Neuroendocrine Neoplasm. / Johnbeck, Camilla Bardram; Mortensen, Jann.

I: PET Clinics, Bind 16, Nr. 2, 2021, s. 191-203.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Johnbeck, CB & Mortensen, J 2021, 'Somatostatin Receptor Imaging PET in Neuroendocrine Neoplasm', PET Clinics, bind 16, nr. 2, s. 191-203. https://doi.org/10.1016/j.cpet.2020.12.011

APA

Johnbeck, C. B., & Mortensen, J. (2021). Somatostatin Receptor Imaging PET in Neuroendocrine Neoplasm. PET Clinics, 16(2), 191-203. https://doi.org/10.1016/j.cpet.2020.12.011

Vancouver

Johnbeck CB, Mortensen J. Somatostatin Receptor Imaging PET in Neuroendocrine Neoplasm. PET Clinics. 2021;16(2):191-203. https://doi.org/10.1016/j.cpet.2020.12.011

Author

Johnbeck, Camilla Bardram ; Mortensen, Jann. / Somatostatin Receptor Imaging PET in Neuroendocrine Neoplasm. I: PET Clinics. 2021 ; Bind 16, Nr. 2. s. 191-203.

Bibtex

@article{c1453331dca64e009ba55fa72593187a,

title = "Somatostatin Receptor Imaging PET in Neuroendocrine Neoplasm",

abstract = "PET/computed tomography (CT) imaging increasingly is used in neuroendocrine neoplasms (NENs) for diagnosis, staging, monitoring, prognostication, and choosing treatment. Somatostatin PET analog tracers have added to the specificity by obtaining higher affinity to somatostatin receptors with 68Ga-labeled or 64Cu-labeled DOTA peptides compared with single-photon emission CT imaging isotopes. PET uptake correlates to tumor grade and is an essential part of theranostics with peptide receptor radionuclide treatment. This article focuses on the literature on head-to-head studies and meta-analyses of different combinations of peptide agonists and a few antagonists. Overall, the published data support the diagnostic capability of PET/CT imaging in NENs.",

keywords = "Humans, Neuroendocrine Tumors/diagnostic imaging, Organometallic Compounds, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Radiopharmaceuticals, Receptors, Somatostatin",

author = "Johnbeck, {Camilla Bardram} and Jann Mortensen",

year = "2021",

doi = "10.1016/j.cpet.2020.12.011",

language = "English",

volume = "16",

pages = "191--203",

journal = "P E T Clinics",

issn = "1556-8598",

publisher = "W.B.Saunders Co.",

number = "2",

}

RIS

TY - JOUR

T1 - Somatostatin Receptor Imaging PET in Neuroendocrine Neoplasm

AU - Johnbeck, Camilla Bardram

AU - Mortensen, Jann

PY - 2021

Y1 - 2021

N2 - PET/computed tomography (CT) imaging increasingly is used in neuroendocrine neoplasms (NENs) for diagnosis, staging, monitoring, prognostication, and choosing treatment. Somatostatin PET analog tracers have added to the specificity by obtaining higher affinity to somatostatin receptors with 68Ga-labeled or 64Cu-labeled DOTA peptides compared with single-photon emission CT imaging isotopes. PET uptake correlates to tumor grade and is an essential part of theranostics with peptide receptor radionuclide treatment. This article focuses on the literature on head-to-head studies and meta-analyses of different combinations of peptide agonists and a few antagonists. Overall, the published data support the diagnostic capability of PET/CT imaging in NENs.

AB - PET/computed tomography (CT) imaging increasingly is used in neuroendocrine neoplasms (NENs) for diagnosis, staging, monitoring, prognostication, and choosing treatment. Somatostatin PET analog tracers have added to the specificity by obtaining higher affinity to somatostatin receptors with 68Ga-labeled or 64Cu-labeled DOTA peptides compared with single-photon emission CT imaging isotopes. PET uptake correlates to tumor grade and is an essential part of theranostics with peptide receptor radionuclide treatment. This article focuses on the literature on head-to-head studies and meta-analyses of different combinations of peptide agonists and a few antagonists. Overall, the published data support the diagnostic capability of PET/CT imaging in NENs.

KW - Humans

KW - Neuroendocrine Tumors/diagnostic imaging

KW - Organometallic Compounds

KW - Positron Emission Tomography Computed Tomography

KW - Positron-Emission Tomography

KW - Radiopharmaceuticals

KW - Receptors, Somatostatin

U2 - 10.1016/j.cpet.2020.12.011

DO - 10.1016/j.cpet.2020.12.011

M3 - Review

C2 - 33648664

VL - 16

SP - 191

EP - 203

JO - P E T Clinics

JF - P E T Clinics

SN - 1556-8598

IS - 2

ER -

ID: 303044003